Nanofiltration of plasma‐derived biopharmaceutical products

Haemophilia - Tập 9 Số 1 - Trang 24-37 - 2003
Thierry Burnouf1, Mirjana Radosevich
1Human Plasma Product Service, Lille, France. [email protected]

Tóm tắt

Summary. This review presents the current status on the use and benefits of viral removal filtration systems – known as nanofiltration – in the manufacture of plasma‐derived coagulation factor concentrates and other biopharmaceutical products from human blood origin.Nanofiltration of plasma products has been implemented at a production scale in the early 1990s to improve margin of viral safety, as a complement to the viral reduction treatments, such as solvent–detergent and heat treatments, already applied for the inactivation of human immunodeficiency virus, hepatitis B and hepatitis C virus. The main reason for the introduction of nanofiltration was the need to improve product safety against non‐enveloped viruses and to provide a possible safeguard against new infectious agents potentially entering the human plasma pool.Nanofiltration has gained quick acceptance as it is a relatively simple manufacturing step that consists in filtering protein solution through membranes of a very small pore size (typically 15–40 nm) under conditions that retain viruses by a mechanism largely based on size exclusion. Recent large‐scale experience throughout the world has now established that nanofiltration is a robust and reliable viral reduction technique that can be applied to essentially all plasma products. Many of the licensed plasma products are currently nanofiltered.The technology has major advantages as it is flexible and it may combine efficient and largely predictable removal of more than 4 to 6 logs of a wide range of viruses, with an absence of denaturing effect on plasma proteins. Compared with other viral reduction means, nanofiltration may be the only method to date permitting efficient removal of enveloped and non‐enveloped viruses under conditions where 90–95% of protein activity is recovered. New data indicate that nanofiltration may also remove prions, opening new perspectives in the development and interest of this technique. Nanofiltration is increasingly becoming a routine step in the manufacture of biopharmaceutical products.

Từ khóa


Tài liệu tham khảo

10.1054/blre.2000.0129

10.1046/j.1365-2141.1996.5161062.x

10.1046/j.1423-0410.1997.00001.x

10.1046/j.1537-2995.1998.38698326337.x

10.1016/S0140-6736(96)91412-9

10.1038/39057

10.1016/S0958-1669(00)00201-9

10.1295/polymj.19.391

10.5360/membrane.14.253

10.1007/978-94-011-0848-5_3

10.1111/j.1423-0410.1996.tb01334.x

Hughes BA, 1996, Evaluation of anti‐viral filters, Dev Biol Stand, 88, 91

Viresolve, 2002, Virus and Application Filtration Guide

Element Data Sheet F1 1996 OMEGA VR TM virus reduction membrane

10.5360/membrane.14.77

10.1295/polymj.19.391

Manabe S., 1996, Removal of virus through novel membrane filtration method, Dev Biol Stand, 88, 81

Ide S. Development of new Planova® membrane – the Planova® 2ON filter. Planova® Workshop Japan A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration. Tokyo:Asahi Kasei Corporation November 1 2000.

10.1295/polymj.22.751

Yamaguchi K, 1991, Microparticle removability of the regenerated cellulose hollow fiber (BMM): an electron microscopic evaluation, J Electron Microsc, 40, 337

Viresolve NFP filters.Data Sheet. Millipore9/1/2001.

Viresolve NFR filters.Data Sheet. Millipore12/99.

Graf EG, 1999, Virus removal by filtration, Dev Biol Stand, 99, 89

Brandwein H, 2000, Membrane filtration for virus removal, Dev Biol Stand, 102:157

10.1046/j.1423-0410.1998.7530181.x

Validation Guide VG‐DV20 Pall ULTIPOR VF Grade DV20 AB style virus removal filter cartridges.Pall BioPharmaceuticals 2000.

Aranha‐CreadoH OshimaK JafariS HowardG BrandweinH.Virus retention by Ultipor VF grade DV50 membrane filters. Pall STR1543.

Aranha‐Creado H, 1997, Virus retention by a hydrophilic triple‐layer PVDF microporous membrane filter, PDA J Pharm Sc Technol, 51, 119

Burnouf T., 1993, Chromatographic removal of viruses from plasma derivatives, Dev Biol Stand, 81, 199

Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products. In:HorowitzB MinorP MorgenthalerJJ BurnoufT McIntoshR PadillaA Thorpe R. (drafting group) Geneva: WHO. BS/01/1941 2002(in press).

10.1055/s-0038-1655911

Rosendaal FR, 1993, A sudden increase in factor VIII inhibitor development in multitransfused hemophilia patients in The Netherlands, Blood, 81, 10.1182/blood.V81.8.2180.2180

10.1111/j.1423-0410.1994.tb01647.x

10.1111/j.1423-0410.1989.tb00832.x

10.1055/s-0037-1615389

Mannucci PM, 1995, Preliminary evaluation of a nanofiltered factor IX concentrate, Thromb Haemost, 73, 737, 10.1055/s-0038-1653859

Yunoki M, 2000, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration

Feldman P, 1998, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology, 47

10.1016/0378-4347(95)00107-T

10.1006/biol.1999.0242

10.1159/000204024

10.1046/j.1365-2516.1999.t01-1-00284.x

10.1111/j.1423-0410.1987.tb02979.x

Romisch J, 1996, Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality, Beitr Infusionsther Transfusionsmed, 33, 220

Nowak T, 1998, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology, 16

10.1016/S0049-3848(00)00339-X

Over J, 1998, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology, 5

10.1016/0378-4347(94)00532-A

10.1016/S0165-022X(01)00221-4

Maeno H, 2000, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration, 21

10.1046/j.1423-0410.2001.00114.x

Chtourou S, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration, 91

10.1111/j.1423-0410.1991.tb00864.x

Rothschild F, 1999, Factor VIII SD‐35‐15: Preliminary Results of a Cross‐Over Pharmacokinetic Study of SD and 35–15 nm Filtered Factor VIII Concentrate Compared to Reference Product (SD Factor VIII Concentrate)

10.1046/j.1423-0410.2000.7810007.x

10.1046/j.1537-2995.1992.32993110761.x

10.1111/j.1423-0410.1992.tb01159.x

Borel‐Derlon A, 2000, Plasma‐Derived Medical Products and Haemostasis: Current Issues and Perspectives

Yap PL, 1992, Clinical Applications of Intravenous Immunoglobulin Therapy, 43

10.1006/biol.1998.0164

10.1006/biol.1996.0036

Dichtelmuller H, 1998, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology, 27

Suomela H, 1998, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology, 38

Hong F, 1998, Safety profile of WinRho anti‐D, Semin Hematol, 35, 9

10.1016/S0378-4347(97)00319-8

Price H, 1999, A Forum for Exchanging Information on the Latest Developments in Virus Removal Technology, 21

Maeno H, 2000, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration, 22

Poulle M, 1994, Large‐scale preparation of highly purified human C1‐inhibitor for therapeutic use, Blood Coag Fibrinolysis, 5, 543

BunchC KavanaghC HeldebrantC BhattacharyaP CraigWC.Alpha‐1 Proteinase Inhibitor (A1PI) Virus Reduction Studies.XVII Congress of the International Society on Thrombosis and Haemostasis Washington DC USA August 1421 1999 no. 912 (Abstracts).

Bunch C, 1999, A Forum for Exchanging Information on the Latest Developments in Virus Removal Technology, 35

10.1006/biol.2001.0273

10.3109/10731190009118582

10.1006/biol.2000.0246

10.1089/107999001753289523

10.1046/j.1537-2995.1999.39111169.x

10.1046/j.1365-2516.2002.00618.x

10.1046/j.1423-0410.1998.7530178.x

10.1016/S0140-6736(00)02706-9

10.1016/S0140-6736(97)24002-X

10.1046/j.1537-2995.1998.38998408999.x

10.1136/bmj.325.7365.633

10.1007/BF00690454

Kuroda Y, 1983, Creutzfeldt‐Jakob disease in mice: persistent viremia and preferential replication of virus in low density lymphocytes, Infect Immun, 41, 154, 10.1128/iai.41.1.154-161.1983

Hunter N, 2002, Can prion diseases be transmitted between individuals via blood transfusion: evidence from sheep experiments, Dev Biol, 108, 93

10.1111/j.1348-0421.1991.tb01544.x

10.1046/j.1537-2995.2001.41040449.x

MacGregor I, 1999, Normal prion protein is found in human plasma, but is removed by the SNBTS plasma fractionation process, Thromb Haemost, 82, 86

10.1046/j.1423-0410.2000.7820086.x

10.1046/j.1537-2995.1999.39111169.x

10.1016/S0140-6736(85)91576-4

10.5360/membrane.18.357

10.1007/978-94-011-0437-1_99

10.1006/biol.2001.0269

10.1006/biol.1996.0013

Blum M, 1998, A bovine spongiform encephalopathy validation study for aprotinin and bovine serum albumin, Biopharm, 11, 28

Carter J, 2002, An overview of viral filtration in biopharmaceutical manufacturing, Eur J Parent Sci, 7, 72

Thông tin
Thông tin xuất bản

Haemophilia

Tập 9 Số 1

24-37

Thông tin tác giả